Log in
Sign up
Read & Download your Issue of Thursday – January 28 FNN News
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
- In the Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
- Patients on stable treatment with mycophenolate for at least 6 months before randomisation could participate.
- The aim of this subgroup analysis was to examine the efficacy and safety of nintedanib by mycophenolate use at baseline.
Source: The Lancet
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial
- The benefit of sildenafil in patients with advanced idiopathic pulmonary fibrosis (IPF) at risk of poor outcomes from pulmonary hypertension, whether already present or likely to develop, is uncertain.
- This study aimed to assess the efficacy and safety of sildenafil added to pirfenidone versus placebo added to pirfenidone for 52 weeks in patients with advanced IPF and at risk of group 3 pulmonary hypertension.
Source: The Lancet
Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials
- Fevipiprant, an oral antagonist of the prostaglandin D 2 receptor 2, reduced sputum eosinophils and improved lung function in phase 2 trials of patients with asthma.
- This study aimed to investigate whether fevipiprant reduces asthma exacerbations in patients with severe asthma.
- Although neither trial showed a statistically significant reduction in asthma exacerbations after adjusting for multiple testing, consistent and modest reductions in exacerbations rates were observed in both studies with the 450 mg dose of fevipiprant.
Source: The Lancet
Development of nanoparticle-delivery systems for antiviral agents: A review
- The COVID-19 pandemic has resulted in unprecedented increases in sickness, death, economic disruption, and social disturbances globally.
- This article outlines the major classes of antivirals, summarizes the challenges currently limiting their efficacy, and highlights how nanoparticles can be used to overcome these challenges.
- Recent studies on the application of antiviral nanoparticle-based delivery systems are reviewed and future directions are described.
Source: ScienceDirect
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
- Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19).
- Whether convalescent plasma with high antibody levels rather than low antibody levels is associated with a lower risk of death is unknown.
- Among patients hospitalized with Covid-19 who were not receiving mechanical ventilation, transfusion of plasma with higher antiāSARS-CoV-2 IgG antibody levels was associated with a lower risk of death than transfusion of plasma with lower antibody levels.
Source: NEJM
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
- The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction.
- Its effect on cardiovascular outcomes is unknown.
- Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo.
Source: NEJM
- Download Now FNN Issue for January 2021, from this LINK.
- Read more from FADIC Blog, with many articles with evidence basedĀ articles.
- Learn More Through FADICĀ® – Online Programs & Mini-Courses.
- Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
- Read More Now about FADIC Pharmacy Events to get more Experience.
Course Copyrights:
All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.
FeedBack
FADIC 2021 Pharmacotherapy Daily News
(FNN)
Directed By/ Rasha Abdelsalam
FADIC Pharmacy’s Daily Newspaper works like this:
- Each business morning, you receive an email message with the text of that dayās FNN.
- The message has a link to a PDF file that can be viewed or printed format.
- Issues for the past reports.
Each and every business day, things change!!
- More articles are published
- New drugs are approved
- Research is presented at medical meetings, policy decisions affecting practice are debated and confirmed.
By subscribing to the FADIC 2020 Pharmacotherapy Daily News (FNN), a daily publication of the Daily News Network āFNNā will be sent to your Email.
š Sample of Every Day NewsĀ š„
š Sample of Monthly NewsletterĀ š„
You can keep up with whatās important
- You need not to be disturbed with many newsletters crowding your email inbox about everything.
- FADIC FNNās provides you with each business day with a morning email summary of developments in all the areas critical to your clinical practice
FADIC 2021 Pharmacotherapy Daily News (FNN) Daily Emails Contain:
- Just-published articles in the biomedical literature
- Emphasis on the FOUR weekly major important medical journals such asĀ āLancet, BMJ, JAMA, and NEJMā
- In addition to the two internal medicine journals asāAnnals and JAMA Internal Medicineā
- Finally, the leading journals in medical speciality areas such as:Ā āIDSA, JACCP, Annals of Pharmacotherapy, and othersā.
- News briefs covering newly approved drugs, warnings and recalls announced by FDA, Saudi FDA, research at medical meetings.
- Lastly, other important news from International Organizations such asĀ āCDC, WHO, and othersā.
Why FADIC 2021 Pharmacotherapy Daily News (FNN) ?
- It helps to keep up with the literature!
- Provide you with theĀ Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
- Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!
SubscribeĀ to FADIC 2021 Pharmacotherapy Daily News (FNN), for a publication of E-News
Read & Download FNN Issue 8 of April 2020 FNN News
With FADIC 2021 Pharmacotherapy Daily News (FNN), you Will ā¦
Receive email notification everyday morning
As we all know, the world of clinical research is changing constantly. All medical news, clinical guidelines, and updates become available in your daily medical news issue.
You can read & download news every day
You can access your daily medical everyday morning, once you receive the email notification in the morning, and entre the website, and download your news issue.
You can print your daily news for work
You will receive your FNN daily medical news from international journals, and you can print it and share the latest journal club in your
The full-Text source will be available for you
If you need to know any further details or full-teat for any news, you can open the corresponding links that support you with further details.
You’ll Also Get These Awesome Bonusesā¦
Bonus #1. Download monthly FNN international issues (Value 300$)
As well as the daily news, there will be a monthly issue with the most important news all over the month, that will help you to stay updated, you can download it and print.
Bonus #2. Your FNN website account support (200$ Value)
You will have your own account in FNN Medical news, in FADIC website, that enables you to follow up on all the previous or missed issues, and read them to catch up on any missed news and download all of them.
Subscribe NOW in FNN – Special Offers for Group and Organisational Subscription
Course Copyrights:
All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.